ScreenerHero

LRMR Larimar Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · larimartx.com
2.750USD-1.08%Mkt Cap: 285.68M $P/E: —

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap285.68M USD
Enterprise Value138.87M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-165.67M USD
Revenue/Share—
Last Price2.750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees71
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.62
PEG—
EV/EBITDA-0.78
EV/Revenue—
P/S—
P/B2.28
EPS (TTM)-1.99
EPS (Forward)-1.06
52W Range
2.7151% of range6.420
52W High6.420 USD
52W Low2.715 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-212.17%
ROA-113.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-113.20M USD
CapEx (TTM)91.00K USD
FCF Margin—
FCF Yield-32.97%
Net Debt-151.31M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.05
Current Ratio4.70
Quick Ratio4.58
Book Value/Sh1.22 USD
Cash/Share1.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateMay 29, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.40 USD
Upside (mean)+423.6%
Target Range5.000 USD – 26.00 USD
5.000+423.6% to mean26.00
# Analysts10
Ownership
Shares Out.103.88M
Float57.90M
Insiders1.15%
Institutions93.42%
Short Interest
Short Ratio15.1d
Short % Float20.66%
Short % Out.13.37%
Shares Short13.89M
Short (prev mo.)13.44M
Technical
SMA 503.854 (-28.7%)
SMA 2003.922 (-29.9%)
Beta0.69
S&P 52W Chg16.45%
Avg Vol (30d)1.21M
Avg Vol (10d)1.69M
Technical Indicators
RSI (14)25.6
MACD-0.2990
MACD Signal-0.2230
MACD Hist.-0.0761
BB Upper4.359 USD
BB Middle3.451 USD
BB Lower2.543 USD
BB Width52.61%
ATR (14)0.2024 USD
Vol Ratio (20d)0.50x